Hims & Hers Health (HIMS) has been one of the market’s standout growth stocks in recent years. The company has successfully ...

DelveInsight's Sarcopenia Market Insights report includes a comprehensive understanding of current treatment practices, ...

Shares of Hims & Hers Health plunged by more than 30% after Danish weight-control drug maker Novo Nordisk abruptly pulled out of a partnership with the telehealth firm on the distribution of Wegovy.

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...